NOEM NOEM Stock Issued During Period Value Fair Value Of Representative Shares Deferred Until IPO

Stock Issued During Period Value Fair Value Of Representative Shares Deferred Until IPO at other companies

Evommune EVMN

$577.47K—

Cineverse Corp.CNVS

$9K—

MillerKnollMLKN

$1.1M+10.0%

BioCryst PharmaceuticalsBCRX

$33K+450%

PennyMac Financial Services, Inc.PFSI

$96K+68.4%

OS TherapiesOSTX

$289.2K-80.0%

Operating income-$196.7K-15.2%

Net income$309.2K-23.9%

EPS (diluted)-$0.01—

Cash & equivalents$26.1K-95.9%

Total debt$11.7K—

Total equity-$2.0M-33.3%

Total assets$72.1M+1.7%

Operating cash flow-$1.1M-237%

Market cap$100.08M+3.5%

P/E64.4×-47.0×

Return on equity-90.8%—

Current ratio2.6×+0.7×

Reported directly by NOEM in its filing.

Tagged under the XBRL concept noemu:StockIssuedDuringPeriodValueFairValueOfRepresentativeSharesDeferredUntilIPO.

The official record: NOEM’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is NOEM's stock issued during period value fair value of representative shares deferred until IPO?: NOEM (NOEM) reported stock issued during period value fair value of representative shares deferred until IPO of $19.32K in Q4 2024.
What does stock issued during period value fair value of representative shares deferred until IPO mean?: Represents the fair market value of shares issued to representatives or underwriters as compensation for services rendered, often deferred until a liquidity event. It serves as a measure of non-cash compensation costs associated with corporate financing.